Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 11%

Bulls say

Dynavax Technologies Corp has demonstrated substantial growth in the sales of its HEPLISAV-B product, reporting a 39% year-over-year increase in 4Q24 sales and a 26% increase for the full fiscal year 2024, with total sales reaching $268.4 million. The company's market share for HEPLISAV-B has expanded to approximately 44% by the end of 2024, with future sales anticipated to grow due to strong penetration in the eligible adult market and re-vaccination practices, projecting net revenue guidance of $305 million to $325 million for FY25. Moreover, Dynavax's advocacy for a $400 million share repurchase program reinforces its confidence in sustaining long-term market opportunities and achieving a dominant share within the anticipated $900 million hepatitis B vaccination market by 2030.

Bears say

Dynavax Technologies Corp faces significant challenges that contribute to a negative outlook on its stock. The company's future candidates in clinical development may fail to meet efficacy endpoints, coupled with market conditions and competitive pressures that could hinder successful commercialization. Additionally, Dynavax's financial history is marked by losses, highlighting the lack of a sustainable profitability track record, which exacerbates concerns regarding the ability to effectively develop and launch its pipeline candidates.

Dynavax Technologies (DVAX) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Buy based on their latest research and market trends.

According to 9 analysts, Dynavax Technologies (DVAX) has a Buy consensus rating as of Aug 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.